Selected article for: "genetic variation and human population"

Author: Davis, C. Todd; Chen, Li-Mei; Pappas, Claudia; Stevens, James; Tumpey, Terrence M.; Gubareva, Larisa V.; Katz, Jacqueline M.; Villanueva, Julie M.; Donis, Ruben O.; Cox, Nancy J.
Title: Use of Highly Pathogenic Avian Influenza A(H5N1) Gain-Of-Function Studies for Molecular-Based Surveillance and Pandemic Preparedness
  • Document date: 2014_12_12
  • ID: uz7vqq3r_10
    Snippet: Due to the continuous evolution and antigenic drift detected in many subtypes of avian and swine influenza viruses, prioritization of CVV development is required. To meet this need and prioritize other research decisions, the Influenza Risk Assessment Tool (IRAT) was developed by the Influenza Division at the CDC together with a global consortium of animal and public health experts to offer a standardized set of considerations to be applied when .....
    Document: Due to the continuous evolution and antigenic drift detected in many subtypes of avian and swine influenza viruses, prioritization of CVV development is required. To meet this need and prioritize other research decisions, the Influenza Risk Assessment Tool (IRAT) was developed by the Influenza Division at the CDC together with a global consortium of animal and public health experts to offer a standardized set of considerations to be applied when evaluating viruses with pandemic potential (47) . The tool uses an additive model, based on multiattribute decision analysis, to integrate weighted elements from both laboratory and field observations. Collectively, assessment of the molecular characteristics of circulating virus, together with factors such as incidence of human infections, population immunity, geographic or host distribution, antigenic variation, and/or extent of overall genetic diversification, provides an objective approach to measuring potential risk of a given strain, subtype, or group of viruses (47) .

    Search related documents:
    Co phrase search for related documents
    • additive model and human infection: 1, 2, 3
    • additive model and influenza virus: 1
    • additive model and pandemic potential: 1
    • additive model and potential risk: 1
    • additive model and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • antigenic drift and continuous evolution: 1, 2
    • antigenic drift and genetic diversification: 1
    • antigenic drift and human infection: 1, 2, 3, 4, 5, 6, 7
    • antigenic drift and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
    • antigenic drift and need meet: 1
    • antigenic drift and pandemic potential: 1, 2, 3
    • antigenic drift and population immunity: 1, 2, 3
    • antigenic drift and potential risk: 1, 2
    • antigenic drift and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • antigenic drift and public health animal: 1
    • antigenic drift and virus group: 1, 2
    • antigenic drift continuous evolution and continuous evolution: 1
    • antigenic variation and human infection: 1, 2
    • antigenic variation and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17